⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for nhl

Every month we try and update this database with for nhl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesNCT03465540
Multiple Myelom...
Acute Myeloid L...
Non-Hodgkins Ly...
Myelodysplastic...
AML
MDS
NHL
AMG 397
Dexamethasone
Azacitidine
18 Years - 65 YearsAmgen
Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)NCT00717925
Lymphoma, B-Cel...
Inotuzumab Ozog...
20 Years - 74 YearsWyeth is now a wholly owned subsidiary of Pfizer
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk ChemotherapyNCT02178475
Chemotherapy-in...
18 Years - Amgen
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)NCT02631044
Non-Hodgkin Lym...
Diffuse Large B...
Follicular Lymp...
Mantle-cell Lym...
Primary Mediast...
JCAR017 (lisoca...
JCAR017 (lisoca...
18 Years - Juno Therapeutics, a Subsidiary of Celgene
SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaNCT00796731
Lymphoma
Non-Hodgkin
SAR3419
18 Years - Sanofi
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantNCT03739502
AML
NHL
Hodgkin Disease
All
Myelodysplastic...
Hyperbaric oxyg...
18 Years - 70 YearsUniversity of Rochester
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced ThrombocytopeniaNCT01516619
Non-Hodgkin Lym...
Romiplostim
18 Years - IRCCS San Raffaele
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma PatientsNCT04844866
Diffuse Large B...
MB-CART2019.1
R-GemOx or BR p...
18 Years - Miltenyi Biomedicine GmbH
Nonmyeloablative Allo SCT for the Treatment of Hematologic DisordersNCT00636909
AML
ALL
CML Chronic Pha...
CLL
MDS
RELAPSED NON-HO...
APLASTIC ANEMIA
MULTIPLE MYELOM...
MYELOPROLIFERAT...
Cyclophosphamid...
fludarabine
cyclosporine
methotrexate
G-CSF
- 65 YearsBeth Israel Deaconess Medical Center
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLNCT01851551
Non-Hodgkin's L...
Diffuse Large B...
Mantle Cell Lym...
Vincristine Sul...
18 Years - Acrotech Biopharma Inc.
Infusion of Allogeneic, 3rd Party CD19-specific T CellsNCT02274506
Blood And Marro...
Leukemia
Lymphoma
Cyclophosphamid...
Fludarabine
T-Cell Infusion
18 Years - 70 YearsM.D. Anderson Cancer Center
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.NCT06022029
Triple Negative...
Diffuse Large B...
Follicular Lymp...
Lymphoma, Non-H...
Mantle Cell Lym...
Bladder Cancer
Uveal Melanoma,...
Cervix Cancer
Carcinoma in Si...
Head and Neck S...
Skin Cancer
Metastatic Canc...
Tumor, Solid
Tumor Recurrenc...
ONM-501
Cemiplimab
18 Years - OncoNano Medicine, Inc.
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaNCT01306643
Indolent Non-Ho...
Follicular Lymp...
Small Lymphocyt...
Marginal Zone L...
Idelalisib
18 Years - Gilead Sciences
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's LymphomaNCT00285428
Non-Hodgkin's L...
hA20-humanized ...
18 Years - Gilead Sciences
Randomized Double Cord Blood Transplant StudyNCT00067002
Leukemia, Lymph...
Leukemia, Myelo...
Leukemia, Myelo...
Lymphoma, Non-H...
Expanded alloge...
One Unmanipulat...
Rituxan
Melphalan
Thiotepa
Fludarabine
Cyclophosphamid...
Mesna
Total body irra...
1 Month - 80 YearsM.D. Anderson Cancer Center
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood CancersNCT00089596
Acute Lymphocyt...
Acute Myeloid L...
Myelodysplastic...
Non-Hodgkin Lym...
Chronic Myeloge...
Expansion of um...
12 Years - 60 YearsViaCell
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune SystemNCT06385522
NHL
Cutaneous T Cel...
Peripheral T-ce...
BITR2101
18 Years - Boston Immune Technologies and Therapeutics
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLNCT01585688
Non-Hodgkin's L...
Chronic Lymphoc...
hLL1-DOX (IMMU-...
18 Years - Gilead Sciences
A Study of Revlimid in the Treatment of Non-Hodgkin's LymphomaNCT00413036
Lymphoma, Non-H...
lenalidomide
18 Years - Celgene
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionNCT02836925
Indolent B-cell...
Hepatitis C
Ledipasvir+Sofo...
Sofosbuvir+Velp...
18 Years - Fondazione Italiana Linfomi - ETS
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaNCT00283439
Chemotherapy-In...
Hodgkin's Lymph...
Non-Hodgkin's L...
Cancer
Oncology
Thrombocytopeni...
AMG 531
18 Years - Amgen
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaNCT01352312
Chronic Lymphoc...
B-Cell Non-Hodg...
Bendamustine
Pentostatin
Ofatumumab
18 Years - Thomas Jefferson University
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLNCT00577161
Non-Hodgkin's L...
fludarabine and...
fludarabine, ri...
18 Years - CTI BioPharma
Infusion of Allogeneic, 3rd Party CD19-specific T CellsNCT02274506
Blood And Marro...
Leukemia
Lymphoma
Cyclophosphamid...
Fludarabine
T-Cell Infusion
18 Years - 70 YearsM.D. Anderson Cancer Center
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.NCT06022029
Triple Negative...
Diffuse Large B...
Follicular Lymp...
Lymphoma, Non-H...
Mantle Cell Lym...
Bladder Cancer
Uveal Melanoma,...
Cervix Cancer
Carcinoma in Si...
Head and Neck S...
Skin Cancer
Metastatic Canc...
Tumor, Solid
Tumor Recurrenc...
ONM-501
Cemiplimab
18 Years - OncoNano Medicine, Inc.
Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell LymphomaNCT01560117
Follicular T-NH...
Rituximab Maint...
Rituximab
18 Years - Arbeitsgemeinschaft medikamentoese Tumortherapie
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGNCT00061425
Non-Hodgkin's L...
Lymphoma, B-Cel...
radiolabeled ep...
18 Years - Gilead Sciences
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's LymphomaNCT00308087
Lymphoma, Folli...
Sargramostim (L...
Rituximab
18 Years - Sanofi
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228NCT05737628
Lymphoma
BYON4228 + Ritu...
18 Years - Byondis B.V.
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLNCT03019666
Multiple Myelom...
Non-Hodgkin Lym...
Diffuse Large B...
Mantle-Cell Lym...
Follicular Lymp...
Indolent B Cell...
Primary Mediast...
Lymphoplasmacyt...
Nicotinamide Ex...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNCT04594642
B-cell Non Hodg...
Diffuse Large B...
High-grade B-ce...
Follicular Lymp...
AZD0486 IV
18 Years - 130 YearsAstraZeneca
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLNCT03019666
Multiple Myelom...
Non-Hodgkin Lym...
Diffuse Large B...
Mantle-Cell Lym...
Follicular Lymp...
Indolent B Cell...
Primary Mediast...
Lymphoplasmacyt...
Nicotinamide Ex...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell LymphomaNCT02715843
Non-Hodgkin's B...
MT-3724
18 Years - Molecular Templates, Inc.
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell LymphomaNCT01653067
Diffuse Large B...
Rituximab, Tems...
18 Years - University Hospital Heidelberg
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCLNCT05641428
NHL
DLBCL - Diffuse...
ARI-0001
Axi-cel
18 Years - 80 YearsUniversity Medical Center Groningen
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune SystemNCT06385522
NHL
Cutaneous T Cel...
Peripheral T-ce...
BITR2101
18 Years - Boston Immune Technologies and Therapeutics
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationNCT00038818
Chronic Myeloge...
Multiple Myelom...
Non Hodgkin's L...
Hodgkin's Disea...
Chronic Lymphoc...
CD8 Depleted Do...
- M.D. Anderson Cancer Center
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLNCT03740529
Chronic Lymphoc...
Waldenstrom Mac...
Mantle Cell Lym...
Marginal Zone L...
B-cell Lymphoma
Small Lymphocyt...
Pirtobrutinib
Venetoclax
Rituximab
18 Years - Eli Lilly and Company
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHLNCT02151903
B-cell Non-Hodg...
DI-Leu16-IL2
18 Years - Alopexx Oncology, LLC
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's LymphomaNCT00147953
Non-Hodgkin's L...
Rituximab
Total nodal irr...
18 Years - University of Cologne
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersNCT03314974
Acute Leukemia
Acute Myeloid L...
Acute Lymphobla...
Lymphoma
Chronic Myeloge...
Plasma Cell Leu...
Myeloproliferat...
Myelofibrosis
Myelodysplasia
Refractory Anem...
High Risk Anemi...
Chronic Lymphoc...
Small Lymphocyt...
Marginal Zone B...
Follicular Lymp...
Lymphoplasmacyt...
Mantle-Cell Lym...
Prolymphocytic ...
Diffuse Large C...
Lymphoblastic L...
Burkitt Lymphom...
High Grade Non-...
Multiple Myelom...
Juvenile Myelom...
Biphenotypic/Un...
MRD Positive Le...
Natural Killer ...
Acquired Bone M...
HSCT with TBI R...
HSCT with Non-T...
- 60 YearsMasonic Cancer Center, University of Minnesota
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)NCT00499239
Non-Hodgkin's L...
Chronic Lymphoc...
Multiple Myelom...
GS-9219
18 Years - Gilead Sciences
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma CasesNCT00538551
Hodgkin Disease
Lymphoma, Non-H...
Database
14 Years - 85 YearsKing Faisal Specialist Hospital & Research Center
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHLNCT04206943
Acute Lymphobla...
Non Hodgkin Lym...
Car-T Cell Ther...
3 Years - 65 YearsAcibadem University
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasNCT01282424
Follicular Lymp...
Small Lymphocyt...
Lymphoplasmacyt...
Marginal Zone L...
Idelalisib
18 Years - Gilead Sciences
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's LymphomaNCT01889797
Indolent Non-Ho...
Arm A: Rituxima...
Arm B: GA101
18 Years - PrECOG, LLC.
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCLNCT05641428
NHL
DLBCL - Diffuse...
ARI-0001
Axi-cel
18 Years - 80 YearsUniversity Medical Center Groningen
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)NCT00299494
B-Cell Lymphoma
inotuzumab ozog...
inotuzumab ozog...
inotuzumab ozog...
Rituximab
18 Years - Pfizer
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaNCT00556699
Non-Hodgkin's L...
rituximab
SGN-40
18 Years - Genentech, Inc.
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesNCT03588598
Chronic Lymphoc...
Small Lymphocyt...
B-Cell Non-Hodg...
SHC014748M
18 Years - 75 YearsNanjing Sanhome Pharmaceutical, Co., Ltd.
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow InvolvementNCT00992758
Lymphoma, Non-H...
Iodine-131 Anti...
18 Years - GlaxoSmithKline
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid MalignanciesNCT00968760
Lymphoma
B-cell Lymphoma
Leukapheresis
Stem Cell Trans...
CD19-specific T...
IL-2
Carmustine
Etoposide
Cytarabine
Melphalan
18 Years - 75 YearsM.D. Anderson Cancer Center
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's LymphomaNCT00994643
High Risk Non-H...
Rituximab
Interleukin-2
18 Years - Thomas Jefferson University
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaNCT00878254
Mantle-Cell Lym...
G-CSF
Rituximab
Cyclophosphamid...
Cytarabine
Doxorubicin
Etoposide
Ifosfamide
Leucovorin
Mesna
Methotrexate
Vincristine
18 Years - University of Miami
Safety Study of NHL With 90Y-hLL2 IgGNCT00421395
NHL
B-cell NHL
Non-Hodgkins Ly...
90Y-hLL2
18 Years - Gilead Sciences
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabNCT00724971
Lymphoma, B-Cel...
Inotuzumab Ozog...
Rituximab (Ritu...
20 Years - 75 YearsPfizer
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLNCT01728207
Non-hodgkin's L...
Follicular Lymp...
Mantle Cell Lym...
Marginal Zone L...
Chronic Lymphoc...
Small Lymphocyt...
IMMU-114
18 Years - Gilead Sciences
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid MalignanciesNCT00048737
Lymphoma
Leukemia
Zevalin Radioim...
Rituximab
Fludarabine
Cyclophosphamid...
Allogeneic Stem...
18 Years - 70 YearsM.D. Anderson Cancer Center
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against DoxorubicinNCT00268853
Diffuse Large-C...
CPOP-R
CHOP-R
18 Years - CTI BioPharma
Ofatumumab for Initial Systemic Treatment of Indolent B-cell LymphomaNCT01239394
Follicular Lymp...
Marginal Zone L...
Small Lymphocyt...
ofatumumab
18 Years - Massachusetts General Hospital
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.NCT02670317
Lymphoma, B-Cel...
Obinutuzumab
Ibrutinib
CHOP
18 Years - 60 YearsFondazione Italiana Linfomi - ETS
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHLNCT04240704
Non-Hodgkins Ly...
Chronic Lymphoc...
JBH492
18 Years - Novartis
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaNCT00452127
Non-Hodgkin's L...
PRO131921
18 Years - Genentech, Inc.
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589
Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's LymphomaNCT00115193
Non-Hodgkin's L...
pegfilgrastim
pegfilgrastim
18 Years - Amgen
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's LymphomaNCT00285428
Non-Hodgkin's L...
hA20-humanized ...
18 Years - Gilead Sciences
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior TherapiesNCT00670592
Non-Hodgkin's L...
Hodgkin's Lymph...
HCD122
18 Years - Novartis
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell TransplantNCT00901225
Multiple Myelom...
Non-Hodgkins Ly...
Hodgkins Diseas...
G-CSF plus Pler...
18 Years - 75 YearsDuke University
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaNCT00810576
Lymphoma
Vorinostat
Bortezomib
18 Years - M.D. Anderson Cancer Center
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)NCT03768310
Non-hodgkin Lym...
Acute Lymphobla...
CD19.CAR-multiV...
CD19.CAR-multiV...
1 Year - 75 YearsBaylor College of Medicine
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom MacroglobulinemiaNCT02952508
Waldenstrom Mac...
Multiple Myelom...
Chronic Lymphoc...
Small Lymphocyt...
Lymphoplasmacyt...
Marginal Zone L...
Mantle Cell Lym...
Diffuse Large B...
Central Nervous...
Iopofosine I 13...
Iopofosine I 13...
Iopofosine I 13...
18 Years - Cellectar Biosciences, Inc.
Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHLNCT03042585
Relapsed Non Ho...
Refractory Non-...
Total body irra...
18 Years - Loyola University
A Study Of Panobinostat In Children With Refractory Hematologic MalignanciesNCT01321346
Lymphoblastic L...
Myelogenous Leu...
Hodgkin's Disea...
Non-Hodgkin's L...
Panobinostat
Cytarabine
Panobinostat
8 Years - 21 YearsTherapeutic Advances in Childhood Leukemia Consortium
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaNCT00992446
Adult Diffuse L...
B-Cell Non-Hodg...
Follicular Lymp...
Mantle Cell Lym...
Non-Hodgkin Lym...
T-Cell Non-Hodg...
Autologous Hema...
Bortezomib
Carmustine
Cytarabine
Etoposide
Melphalan
Rituximab
Vorinostat
18 Years - Fred Hutchinson Cancer Center
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins LymphomaNCT00577629
Lymphoma, B-Cel...
cyclophosphamid...
etoposide
rituximab
cytarabine
doxorubicin
tositumomab
18 Years - Duke University
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesNCT01471067
Blood And Marro...
Leukemia
Lymphoma
Transplantation...
Transplantation...
Melphalan
Fludarabine
Mycophenolate m...
Tacrolimus
Cord Blood Infu...
Rituximab
ATG
Busulfan
Clofarabine
Total Body Irra...
1 Year - 80 YearsM.D. Anderson Cancer Center
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableNCT00876122
Non-Hodgkin's L...
GDC-0941
18 Years - Genentech, Inc.
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLNCT05702853
B-cell Non Hodg...
Chronic Lymphoc...
Cyclophosphamid...
Fludarabine Inj...
CD19-CD34t meta...
18 Years - Medical University of South Carolina
Carfilzomib Plus Belinostat in Relapsed/Refractory NHLNCT02142530
Non-Hodgkin Lym...
Diffuse Large B...
Mantle Cell Lym...
Follicular Lymp...
Peripheral T-ce...
Carfilzomib
Belinostat
18 Years - Massachusetts General Hospital
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHLNCT01914744
Non-Hodgkin Lym...
Hepatitis B Rea...
Entecavir
Lamivudine
18 Years - 80 YearsFudan University
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: